# ITI-007 (Lumateperone Tosylate) for Schizophrenia

> **NCT03817528** · PHASE2 · TERMINATED · sponsor: **New York State Psychiatric Institute** · enrollment: 4 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** ITI-007

## Key facts

- **NCT ID:** NCT03817528
- **Lead sponsor:** New York State Psychiatric Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-03-01
- **Primary completion:** 2020-09-23
- **Final completion:** 2020-09-23
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** ITI-007 approved by FDA
- **Last updated:** 2021-11-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03817528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03817528, "ITI-007 (Lumateperone Tosylate) for Schizophrenia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03817528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*